Regdanvimab
Monoclonal antibody
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion.
Nº Q105687595 ★★
Uncommon · Knowledge
Regdanvimab
Monoclonal antibody
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion.
Last price
—
Floor price
—
7-day median
—
30-day sales
0
30-day range
—
In circulation
0
Price history
median
low – high
sales
No sales in this period
Show table
| Date | median | Low | High | sales |
|---|
Sales history
- Last sale
- —
- 30-day average
- —
- 30-day low
- —
- 30-day high
- —
- Sales 7d
- 0
- Sales 30d
- 0
No sales yet.
Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.
From Wikipedia
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein. The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis. Regdanvimab was authorized for medical use in the European Union in November 2021.
Text: Wikipédia, CC BY-SA 4.0. ·
Related cards
Bamlanivimab
Experimental antibody treatment for COVID-19
Nº Q100391783 ★★
GS-441524
Metabolite
Nº Q94518604 ★
Remdesivir
Chemical compound and antiviral drug
Nº Q28209496 ★★★
Molnupiravir
Chemical compound
Nº Q96376832 ★★
Nirmatrelvir
Chemical compound
Nº Q106405348 ★★
SARS-CoV-2
Virus that causes COVID-19
Nº Q82069695 ★★★★